Lowenstein Sandler represented Crown Laboratories in the transaction. Crown Laboratories, Inc. (“Crown”), a leading, fully integrated global skincare company, announced its agreement with Eclipse MedCorp LLC, […]
Crown Laboratories’ Acquisition of Eclipse MedCorp’s Assets
Signature Brands’ Acquisition of Brand Castle
Lowenstein Sandler represented Signature Brands and its owner Traub Capital Partners in the transaction. Signature Brands, the leading North American manufacturer of dessert decorating products, announced […]
Zelis’ Acquisition of Sapphire Digital
Lowenstein Sandler represented Sapphire Digital in the transaction, while Kirkland & Ellis represented Zelis. Zelis, a leading payments company in healthcare, entered into a definitive agreement […]
Progress’ $258 Million Acquisition of Kemp
Wilmer Cutler Pickering Hale and Dorr advised Progress on the deal, while Lowenstein represented Mill Point Capital. Progress, the leading provider of products to develop, deploy […]
NexPhase Capital’s Investment in Selerix Systems
Lowenstein represented NexPhase Capital in the transaction. NexPhase Capital, LP (NexPhase), an operationally focused private equity firm, completed its investment in Selerix Systems, Inc. (Selerix), a […]
Celldex Therapeutics’ $287.5 Million Common Stock Offering
Lowenstein Sandler represented Celldex Therapeutics in the offering. Celldex Therapeutics, Inc. (Celldex) (Nasdaq: CLDX) executed its $287.5 million public offering of common stock. Jefferies, SVB Leerink, […]